Launch, acquisition and financing all in a day's work for RIGImmune

15 September 2022

Founded by Yale professors Akiko Iwasaki and Anna Marie Pyle, RIGImmune has announced its launch, an acquisition and a financing all in a single day.

The biopharma company is focused on developing a new class of RNA immunotherapeutics, that selectively activate the innate immune sensor retinoic acid inducible gene I (RIG-I), for viruses.

It has immediately announced the acquisition of Subintro, a biotech specializing in the development and delivery of antiviral therapeutics for respiratory diseases caused by RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK